Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GSK2831781 in Healthy Volunteers and Psoriasis Patients
NCT02195349Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2014
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of IMP731 in plaque psoriasis (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Hematology Abnormalities of Potential Clinical Importance (PCI) up to 307 days, Number of Participants With Clinical Chemistry Abnormalities of PCI up to 307 days and 5 more. Started Jul 2014; status: completed.
02
Drugs
IMP731
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02195349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195349.